This Week in Washington: House passes Lower Costs, More Transparency Act and SUPPORT Act Reauthorization; Senate HELP Committee reports SUPPORT Act Reauthorization and three other bills.
The ARC Program strives to increase the number of treatments by promoting innovative scientific design, providing a deeper understanding of regulatory policies, and engaging with patients and their advocates, and other rare disease stakeholders.
SILVER SPRING, Md., Oct. 17, 2022 /PRNewswire/ Today, the U.S. Food and Drug Administration announced it has awarded 19 new grants and two new contracts totaling more than $38
FDA awards over $38m for advancement of rare disease treatments pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
WASHINGTON (dpa-AFX) - The U.S. Food and Drug Administration has awarded 19 new grants and two new contracts totaling more than $38 million in funding mainly to develop medical products to treat
/PRNewswire/ Today, the U.S. Food and Drug Administration announced it has awarded 19 new grants and two new contracts totaling more than $38 million in.
FDA Awards 19 Grants and Two Contracts Related to Rare Diseases, including ALS pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
May 26, 2021 ACT for ALS Act endorsed by I AM ALS, ALS Association and Muscular Dystrophy Association WASHINGTON – On Tuesday, U.S. Senators Chris Coons (D-Del.), co-chair of the Senate ALS Caucus, and Lisa Murkowski (R-Alaska), along with U.S. Representatives Mike Quigley (D-Ill.) and Jeff Fortenberry (R-Neb.) reintroduced the bipartisan, bicameral Accelerating Access to Critical Therapies for ALS Act (ACT for ALS). This legislation would create the infrastructure necessary to fund early access to promising investigational therapies for patients suffering from fast-progressing rare neurodegenerative and terminal diseases, like ALS. “Action to support patients with ALS and discover new therapies is incredibly urgent,”